Drugs / SAR405838
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01985191 | Nov 2013 → Feb 2016 | cancer | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT01636479 | Jul 2012 → Mar 2018 | cancer | Sanofi | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAR405838 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01985191 ↗ |
| Known as | MI-773 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2381408 ↗ |
| Known as | MI-773 (SAR405838) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2381408 ↗ |
| Known as | MI-77301 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2381408 ↗ |
| Action | Inhibit | “SAR405838, an HDM2 inhibitor” PMID 28324749 ↗ Mar 2017 |
| Modality | Small molecule | — CHEMBL2381408 ↗ |
| Route | Oral | “Route of administration: Oral” NCT01636479 ↗ |
| Target | MDM2 | “SAR405838, an HDM2 inhibitor” PMID 28324749 ↗ Mar 2017 |